Global Cancer Therapeutics Market Research Report 2018 to 2023. The Europe cancer therapeutics market is expected to register a CAGR of 6.3% during the forecast period, 2018 to 2023. Germany dominates the market due to growing prevalence of cancer diseases and rapid adoption of new therapy and novel drugs in the country.
Browse Samle Report at: https://www.marketinsightsreports.com/reports/0402398080/europe-cancer-therapeutics-market-segmented-by-drug-type-cancer-type-and-end-user-growth-trends-and-forecast-2018-2023/inquiry
Companies Mentioned are: AMGEN. ASTRAZENECA, BRISTOL-MEYRS SQUIBB COMPANY, BAYER AG, F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, JOHNSON & JOHNSON, MERCK & CO., INC., NOVARTIS AG, AND PFIZER INC., among others.
This independent 89 pages report guarantees you will remain better informed than your competition. With over 200 tables and figures examining the Cancer Therapeutics market, the report gives you a visual, one-stop breakdown of the leading products, submarket and market leader’s market revenue forecasts as well as analysis to 2023.
The Global Cancer Therapeutics market was valued at USD xx million in 2017 and is forecasted to reach USD xx million by 2025, with a CAGR of 6.3% during the forecast period (2018-2023)
High Prevalence and Incidence of Cancer in Europe
Cancer represents second most important cause of death and morbidity in Europe, accounting for 1.9 million deaths every year. According to WHO, Europe comprises only one-eighth of the total world population but has around one-quarter of the total global cancer cases. Around 3.7 million new patients are reported every year in Europe. The factors attributed to rising incidence of cancer in Europe are unhealthy lifestyles and inappropriate diet, obesity and lack of physical activity. The growing incidence and prevalence of cancer are likely to drive the growth of the cancer therapeutics market in Europe during the forecast period. Additionally, growing government initiatives for cancer awareness and strong R&D initiatives from key players are anticipated to drive the market for global cancer therapeutics.
Inequality in Access to Cancer Therapy across Europe
According to a report published by Lung Cancer Europe, various European countries face different levels of inequality in the access for treatment of cancer. The drugs in Europe are approved by the European Medicines Agency (EMA). However, the approval does not define the availability of drugs all across Europe. For instance, Germany provided patients with full access to drugs approved by the EMA for six types of cancer indications between 2006 and 2016. However, Scotland restricted access to 63% of the same drugs. Thus, inequality in the access of cancer therapy across different countries of Europe, coupled with rising cost of cancer treatment, is likely to impede the growth of the cancer therapeutics market in Europe.
Germany to Govern the Market
Germany is anticipated to dominate the Europe cancer therapeutics market, owing to high prevalence of cancer in the country because of unhealthy lifestyles, coupled with growing emphasis on early diagnosis of cancer. For instance, in 2014, Germany accounted for 2, 24,089 number of deaths due to malignant neoplasm. Ease in regulatory approval of biosimilar in treatment of cancer compared to other developed countries, is likely to augment the growth of the cancer therapeutics market in Europe.
Key Developments in the Market
May 2018: TESARO, Inc. in partnership with UK-based Clinigen Group launched managed access program, to provide recurrent ovarian cancer patients in Europe with access to an investigational therapy, niraparib.
November 2017: Novartis AG had applied for the European Medicines Agency (EMA) for approval of Kymriah in Europe market. The drug will be used in children and young adults with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
Reasons to Purchase this Report
- Analyzing outlook of the market with the recent trends and Porters five forces analysis. Market dynamics, which essentially consider the factors that are impelling the present market scenario, along with growth prospects of the market over the forecast period.
- Market segmentation analysis, including qualitative and quantitative research, incorporating the impact of economic and non-economic aspects.
- Country-level analysis, integrating the demand and supply forces that are influencing the growth of the market.
- Competitive landscape involving the market share of major players, along with the key strategies adopted for development over the past five years.
- Comprehensive company profiles, covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players.
- 3 months analyst support along with the Market Estimate sheet (in excel).
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. MarketInsightsReports is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resource, automobile, IT, technology and media, food and beverages, and consumer goods, among others.
Contact us for your special interest research needs @email@example.com and we will get in touch with you within 24hrs and help you find the market research report you need.
+1 (704) 266-3234 | firstname.lastname@example.org
Connect With us on:
Maggie McClure is a freelance writer based in Winnipeg. She has written for the Calgary Sun, Reader’s Digest, CBC Online,, Rogers Media and others. When Maggie isn’t busy writing, she’s working as a PSW in an aging care facility. Maggie mostly covers stories concerning vulnerable Canadians. There are several ways to contact Maggie here.